← Back
Research Paper Volume 11, Issue 9 pp 2551—2564

MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

class="figure-viewer-img"

Figure 4. MiR-124 sensitizes HCC cells to cisplatin through suppression of SIRT1. (A) CD133+ and CD133- HepG2 and Huh7 cells were transfected with miR-124 (50 pmol/mL), anti-miR-124 (50 pmol/mL), SIRT1 siRNA (50 pmol/mL) and SIRT1 plasmid (2 μg/mL). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Expression of SIRT1 in these cells was then detected by western blot analysis. *P<0.05 vs. NCO group. #P<0.05 vs. cisplatin + NCO group. &P<0.05 vs. cisplatin + miR-124 group. (B) CD133+ HepG2 and Huh7 cells were transfected with miR-124 (50 pmol/mL) and SIRT1 plasmid (2 μg/mL). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Cell viability was then detected by MTT assays. *P<0.05 vs. cisplatin + NCO group. #P<0.05 vs. cisplatin + miR-124 group. (C) CD133- HepG2 and Huh7 cells were transfected with anti-miR-124 (50 pmol/mL) and SIRT1 siRNA (50 pmol/mL). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Cell viability was then detected by MTT assays. *P<0.05 vs. NCO group. #P<0.05 vs. cisplatin + NCO group. &P<0.05 vs. cisplatin + miR-124 group.